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Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296 S81Results: Population 1: The 135 subjects were, on average, 60.73 years old
and had a BMI of 32.77 kg/m2. The median minimum JSW at inclusion was
3.58 mm (min: 0.30 mm- max: 5.99 mm). After 16 and 30 months follow-
up, the minimum JSW were 3.38 mm (min: 0 mm- max: 5.80 mm) and
2.96 mm (min: 0 mm- max: 5.99 mm), respectively. At 30 months follow-
up, linear regression analysis showed that 85% of the subjects had expe-
rienced a JSW decrease. After 30 months, 61 patients (45.2%) were radio-
graphic progressors. By logistic regression, we observed that patients with
an increase of uColl2-1NO2 over 16 months (> 0.052 nmol/mmol Cr) had
a high probability (82%) of being radiographic progressors (p<0.001). By
contrast, patients with a decrease of uColl2-1NO2 over 16 months (a
decrease more than 0.114 nmol/mmol Cr) had a high probability (80%) of
being nonprogressors (p<0.01).
Population 2: The 182 women were, on average, 53.54 years old and had
a BMI of 35.88 kg/m2. The medianminimum JSWat inclusionwas 3.67 mm
(min: 0.57 mm- max: 7.21 mm). After 18 and 30 months, the minimum
JSW was 3.59 mm (min: 0 mm - max: 6.60 mm) and 3.54 mm (0 mm-6.49
mm), respectively. Linear regression analysis showed that 64% of subjects
experienced a decrease of JSW over 30 months. Among this population,
124 patients (68%) were radiographic nonprogressors while 58 patients
(32%) were radiographic progressors. At baseline, uColl2-1NO2 concen-
tration was 1.25 times higher (p<0.01) in radiographic progressor patients
(median: 0.0254 nmol/mmol Cr; min: 0.0073 - max: 0.1890 nmol/mmol
Cr) compared to the nonprogressor patients (0.0204 nmol/mmol Cr; min:
0.0043 - max: 0.0637 nmol/mmol Cr). By logistic regression in this pop-
ulation, patients with a high uColl2-1NO2 concentration at baseline (i.e.
0.172 nmol/mmol Cr) had a high probability (98%) of being radiographic
progressors (p<0.001). Also patients with an increase ( 0.0362 nmol/
mmol Cr) of uColl2-1NO2 over 16 months had a high probability (92%) of
being radiographic progressors.
Conclusions: The results of the both studies agree well and show
a consistent capability of urinary Coll2-1NO2 to predict knee OA progres-
sion. Speciﬁcally, the 16-month change in urinary Coll2-1NO2 is a useful
predictor of radiographic progression of knee OA over 30 months in two
independent populations totaling a sample size of 317 patients.
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Purpose: To investigate whether change in concentrations over time of
aggrecanase generated ARGS-aggrecan in synovial ﬂuid (SF ARGS) associ-
ates with progression of radiographic knee osteoarthritis (OA) and patient-
reported outcome in subjects with previous meniscectomy.
Methods: We studied 74 subjects whom at ﬁrst examination were mean
(range) 52 (32 to 73) years old and had beenmeniscectomized 18 (15 to 22)
years earlier, with a follow up examination 7.5 (4 to 10) years later. We
obtained synovial ﬂuid, patient-reported outcomes, standing tibiofemoral
and skyline patellofemoral radiographs at both examinations. We
measured SF ARGS by an electrochemiluminescence immunoassay using
an anti-aggrecan antibody (AHP0022; Invitrogen) for capture, and
amonoclonal anti-ARGS (OA-1) for detection. Radiographic outcomes (loss
of joint space, osteophyte progression, and radiographic OA progression)
were based on progression from ﬁrst to second examination of the scores
of joint space narrowing (JSN), osteophytes, and either JSN or osteophytes
or both, scored according to the OARSI atlas; progressionwas deﬁned as an
increase in the respective scores with one or more. Patient-reported
outcomes was assessed by Knee injury and Osteoarthritis Outcome Score
(KOOS) with the ﬁve dimensions, pain, other symptoms, function of daily
living, function in sports and recreation, and knee-related quality of life;
progression was deﬁned as a worsening in the respective score by 10 units
or more. To study the association between the change in levels of SF ARGSbetween examinations and progression of radiographic OA and KOOS, we
created a dichotomous SF ARGS variable (increase or decrease) and used
multivariate logistic regression adjusted for age, gender, body mass index,
time between examinations, and SF ARGS at ﬁrst examination.
Results: SF ARGS levels were mean (and range) 6.66 (0.15-14.58) and 7.06
(0.12-14.71) pmol ARGS/ml at ﬁrst and second examinations respectively,
and showed a correlation between examinations (Pearson's correlation
coefﬁcient ¼ 0.611, P< 0.001). There was a signiﬁcant association between
decreasing levels of SF ARGS and loss of joint space and worsening of KOOS
pain: in subjects with decreasing SF ARGS between examinations, the
likelihood of loss of joint space and worsening of KOOS pain between
examinations was increased 6- and 4-fold, respectively, compared to those
increasing in SF ARGS (Table 1). No signiﬁcant associations were seen
between decreasing SF ARGS and osteophyte progression, or patient-
reported outcomes other than KOOS pain.
Conclusions: In middle-aged subjects with a meniscectomy 18 years
earlier, decreasing levels of SF ARGS over the next four to ten years were
associated with an increased risk for loss of joint space and worsening of
knee pain over the same time period, but showed no association with
other patient-reported outcomes or osteophyte progression.
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CAN THE DIAGNOSTIC AND PROGNOSTIC CAPACITY OF OA BIOMARKERS
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Purpose:: Although many biomarkers are known to have diagnostic and
prognostic capacity for knee OA, few of them are reliable enough to be used
clinically. Some investigators have attempted to improve the diagnostic
performance of biomarkers by measuring two ormore biomarkers together,
but it has not been known if this strategy is indeed useful or not. In this
study, we attempted to know the best possible combinations of biomarkers
for knee OA for the diagnosis and the prediction of disease progression.
Methods: The study included 43 knee OA patients (mean, 71.7 years), and
30 age matched healthy volunteers (mean, 68.5 years). To be included in the
study, an OA patient had to be at least 50 years old, and have medially
involved knee OA in at least one of the knee joints. The diagnosis of knee OA
was based on the ACR criteria, and the knees with the severest stage of OA
(Kellgren-Lawrence grade 4) were excluded from the study because
progression of joint space narrowing was not evaluated with such knees. All
knee OA patients were followed up for 2 years, during which the patients
were asked to visit clinics every 6 months. For these patients, knee radio-
graphs were taken in the weight-bearing ﬁxed-ﬂexion method (Peterfy,
2003), and blood and urine samples were obtained at each visit. Progression
of knee OAwas determined on the radiographs, bymeasuring the narrowest
width between the femur and tibia in the medial compartment. Since
radiographs were obtained every 6 months, we were able to specify the 6-
month periods in which the narrowing actually occurred. Blood and urine
samples were obtained once from the healthy controls.
Fourteen serum biomarkers and 6 urine biomarkers, which have been
reported to associate with the pathology of knee OA, were measured with
serumandurine samples, respectively (Table). Themarkerswere compared
